XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...
Lupin is introducing rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. The medication is used to reduce the risk of major cardiovascular events in patients with coronary artery ...
Rivaroxaban (Xarelto; Bayer/Janssen) has gained an additional indication, this time for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients at increased risk for ...
Aurobindo has obtained the Food and Drug Administration’s green light for rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. Rivaroxaban tablets are used to reduce the risk of ...
Raritan, NJ (September 8, 2011) — Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal ...
A new oral suspension formulation of Xarelto has also been approved by the FDA. The Food and Drug Administration (FDA) has approved Xarelto ® (rivaroxaban) for 2 new pediatric indications: treatment ...
RARITAN, N.J., Dec. 11, 2017 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...
OPEC+ will likely raise oil output on Sunday but probably add less oil from October than in recent months as global demand might be slowing with the end of the driving season, OPEC+ sources said on ...
XARELTO (rivaroxaban) 20mg tablets Janssen Pharmaceuticals announced FDA approval of Xarelto (rivaroxaban) tablets for the prevention of deep vein thrombosis (DVT) that may lead to a pulmonary ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using RIVAROXABAN-TEVA? RIVAROXABAN-TEVA contains the ...
The FDA approved the anticoagulant rivaroxaban (Xarelto, Janssen), to reduce the risk for stroke among patients with non-valvular atrial fibrillation (AF). Approval comes after data from the ROCKET-AF ...
NEW ORLEANS (AP) — The pharmaceutical companies behind the widely advertised blood thinner Xarelto reached a $775 million settlement in 25,000 lawsuits alleging patients were not adequately warned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback